UroGen Pharma (NASDAQ:URGN) Stock Price Up 3.6% – Time to Buy?

UroGen Pharma Ltd. (NASDAQ:URGN) shares traded up 3.6% on Thursday . The stock traded as high as $12.06 and last traded at $12.09. 285,917 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 497,520 shares. The stock had previously closed at $11.66.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price for the company. Finally, HC Wainwright cut their target price on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $38.20.

UroGen Pharma Stock Up 3.1 %

The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a 50 day simple moving average of $10.48 and a 200-day simple moving average of $11.60. The stock has a market capitalization of $554.05 million, a price-to-earnings ratio of -3.82 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. On average, sell-side analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Insider Transactions at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Institutional Trading of UroGen Pharma

Institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new position in shares of UroGen Pharma during the 4th quarter worth $59,000. Lazard Asset Management LLC purchased a new stake in shares of UroGen Pharma in the fourth quarter worth approximately $67,000. Aquatic Capital Management LLC purchased a new stake in shares of UroGen Pharma in the fourth quarter worth approximately $101,000. BNP Paribas Financial Markets increased its position in shares of UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new stake in UroGen Pharma in the fourth quarter worth $126,000. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.